RV 568

Drug Profile

RV 568

Alternative Names: JNJ 49095397; RV-568

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator RespiVert
  • Developer Janssen Biotech; RespiVert
  • Class Antiasthmatics; Antibronchitics; Antihistamines; Small molecules
  • Mechanism of Action Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease
  • No development reported Asthma; Cystic fibrosis; Lung disorders; Seasonal allergic rhinitis

Most Recent Events

  • 22 Jul 2015 No development reported - Phase-II for Chronic obstructive pulmonary disease in United Kingdom (Inhalation,Aerosol)
  • 01 Sep 2014 Janssen Research & Development completes a phase II trial for Chronic obstructive pulmonary disease in Belgium, Canada, Czech Republic, Germany, Hungary, Netherlands, Poland, Russia, Romania, USA and United Kingdom (inhalation) (NCT01867762)
  • 01 Sep 2013 Phase-II clinical trials in Chronic obstructive pulmonary disease in Belgium, Canada, Czech Republic, Germany, Hungary, Netherlands, Poland, Russia, Romania, USA and United Kingdom (Inhalation) after September 2013
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top